Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
about
Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.Therapy for metastatic pancreatic neuroendocrine tumors.A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinibThe up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.The safety of available treatments options for neuroendocrine tumors.Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China.
P2860
Q33598860-1CFE61EA-9122-4823-87A4-2199062B81FAQ34357869-8AF362FC-6837-4184-BDAC-0D0BD67E4645Q35639659-3C24EB62-0409-473D-A533-F3873AD76792Q35713515-B3B4C831-0771-4142-9FA6-050B3FB664B8Q36344419-8BC3F437-4591-4882-9BEF-C22C704515EDQ37130616-A0BE1E25-75F4-460E-AC45-F319F87BC49FQ38358391-636106AD-0229-4133-94A9-ECEBE19A6F4FQ38627885-BD0DD840-E829-4BE4-90FA-34561C1FA9BEQ38931272-12D60C26-0ACB-4B3F-8CEE-3CECD1289CF3Q39201601-922F5EE1-5048-46E5-93DB-2557D4E236D2Q39433254-DE206ABE-61B0-4F96-8329-A86B3988D567Q45062413-3C44640F-0804-4783-97D8-2BAEA6CEA220Q49822908-3B489866-C1E9-429A-98A1-23F796252346Q50529718-D5CF7FA2-3715-4013-B7D0-519AAD94FABE
P2860
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of sunitinib in ...... ancreatic neuroendocrine tumor
@en
Phase II study of sunitinib in ...... ncreatic neuroendocrine tumor.
@nl
type
label
Phase II study of sunitinib in ...... ancreatic neuroendocrine tumor
@en
Phase II study of sunitinib in ...... ncreatic neuroendocrine tumor.
@nl
prefLabel
Phase II study of sunitinib in ...... ancreatic neuroendocrine tumor
@en
Phase II study of sunitinib in ...... ncreatic neuroendocrine tumor.
@nl
P2093
P2860
P1476
Phase II study of sunitinib in ...... ancreatic neuroendocrine tumor
@en
P2093
Akira Sawaki
Chigusa Morizane
Emiko Ohki
Hisato Igarashi
Kazuo Hara
Kenji Yamao
Mami Murakami
Masayuki Imamura
Nobumasa Mizuno
Nobuyuki Kimura
P2860
P2888
P304
P356
10.1007/S10637-012-9910-Y
P577
2012-12-27T00:00:00Z